PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1489413
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1489413
According to Stratistics MRC, the Global Electronic Clinical Outcome Assessment Solutions Market is accounted for $1.5 billion in 2023 and is expected to reach $4.8 billion by 2030 growing at a CAGR of 17.2% during the forecast period. Electronic Clinical Outcome Assessment (eCOA) solutions streamline data collection in clinical trials by digitizing patient-reported outcomes (PROs), clinician assessments, and observer-reported outcomes. These digital platforms, accessible via mobile devices or web portals, enhance data accuracy, patient engagement, and trial efficiency compared to traditional paper-based methods. eCOA solutions facilitate real-time data capture, remote monitoring, and customizable assessments tailored to specific trial protocols.
According to the 'U.S. Investments in Medical and Health Research and Development 2016-2020' report released in January 2022, federal government investment constituted one-quarter (25%) of all medical and health R&D in the U.S., totaling USD 61.5 billion, with the National Institutes of Health (NIH) accounting for 20% (USD 48.9 billion) of such investment in 2020.
Rising operational costs and regulatory requirements associated with clinical research studies
As operational costs associated with clinical research studies continue to rise due to factors such as increased complexity, longer study durations, and higher patient recruitment expenses, there is a growing demand for cost-efficient solutions. eCOA solutions offer a potential avenue for cost savings by streamlining data collection, reducing the need for manual data entry, minimizing site visits, and optimizing resource utilization. Organizations are increasingly adopting eCOA solutions to mitigate rising operational costs and improve overall study efficiency.
Lack of awareness about eCOA solutions
Electronic clinical outcome assessment solutions offer numerous advantages over traditional data collection methods, including real-time data capture, remote monitoring capabilities, and streamlined workflows. However, without awareness of these benefits, organizations may continue to operate with inefficient processes, leading to increased administrative burden, higher costs, and slower study timelines. Missed opportunities for efficiency can hinder progress in clinical research and healthcare delivery.
Growing preference for digital data collection and analysis
Digital data collection and analysis streamline data management processes, leading to improved efficiency and productivity. Electronic clinical outcome assessment solutions automate tasks such as data entry, data cleaning, and data analysis, reducing administrative burden, minimizing turnaround times, and accelerating study timelines. Healthcare providers, researchers, and pharmaceutical companies can allocate resources more effectively and focus on core activities, leading to cost savings and faster research outcomes propelling the market growth.
Cost of implementation and ongoing maintenance
Implementing and maintaining electronic clinical outcome assessment solutions requires dedicated resources, including IT infrastructure, personnel training, and ongoing support. Organizations with limited resources may struggle to allocate sufficient funds and personnel to implement and manage eCOA solutions effectively. As a result, they may face challenges in optimizing system performance, addressing technical issues, and keeping pace with evolving regulatory requirements and industry standards.
Covid-19 Impact
COVID-19 adversely impacted the conduction and management of clinical trials in 2020. However, market stakeholders implemented several measures such as the adoption of eClinical solutions to overcome these challenges and to ensure the continuity of clinical research activities. The pandemic thus helped catalyze the digitalization of clinical trials. Many sponsors, Biopharma companies, medical device firms, & CROs began adopting eClinical solutions to collect data, manage it, and draw useful insights effectively and remotely. Electronic clinical outcomes assessments (eCOAs) support the collection of patient data remotely.
The clinician reported outcome assessment (CLINRO) segment is expected to be the largest during the forecast period
The clinician reported outcome assessment (CLINRO) segment is estimated to have a lucrative growth, as clinicians play a crucial role in interpreting patient-reported outcomes and validating their clinical relevance. Clinician reported outcome assessment assessments help validate the data collected via eCOA solutions by providing clinical context and professional interpretation. This validation enhances the credibility of outcomes measured by eCOA solutions, making them more valuable to researchers, regulators, and healthcare providers.
The patient management & registries segment is expected to have the highest CAGR during the forecast period
The patient management & registries segment is anticipated to witness the highest CAGR growth during the forecast period, as they facilitate better communication between patients and healthcare providers. Through reminders, alerts, and personalized feedback, these systems encourage patient engagement and adherence to treatment plans or study protocols. Improved patient compliance leads to more reliable data collection in clinical trials, enhancing the validity of outcomes measured by electronic clinical outcome assessment solutions.
Asia Pacific is projected to hold the largest market share during the forecast period owing to the large patient pools, outsourcing, and the flow of investment by MNCs and CROs to support clinical research and drug discovery. This is projected to enhance the market growth. India and China are the key markets for clinical research outsourcing for major pharma & biotech companies. Initiatives and acquisitions pertaining to the adoption of eClinical platforms undertaken by key end-users and market players are anticipated to boost usage in the coming years.
North America is projected to have the highest CAGR over the forecast period, owing to the presence of technologically advanced research centers, medical device manufacturers, universities, and hospitals coupled with improved healthcare establishments are expected to drive new drug development activities in the coming years. Moreover, U.S. accounted for the largest market share of North America in 2022, owing to the higher adoption levels of eClinical solutions. As a result, the EvidentIQ Group now has access to Dacima's broad service offering for end-to-end eClinical solutions which includes eCOA.
Key players in the market
Some of the key players in the Electronic Clinical Outcome Assessment Solutions Market include IBM, ArisGlobal, Clario, Clime do Health GmbH, ClinCapture, Cloudbyz, Curebase Inc, Healthentia, ICON Plc, IQVIA Inc., Kayentis, Medidata Solutions, Inc., Merative, ObvioHealth USA, Inc., Oracle Corporation, Parexel International (MA) Corporation, Signant Health, TransPerfect, WCG Clinical and YPrime, LLC
In January 2024, Fortinet and IBM Cloud Collaborate to Help Clients Protect Their Workloads from Increased Cybersecurity Threats. With clients reporting that they are facing new network and application threats, it's critical to have the right ecosystem of technology partners that can unite around a shared mission of protecting their clients from risk.
In January 2024, IBM and The Government of Spain Collaborate to Advance National AI Strategy and Build the World's Leading Spanish Language AI Models. That will allow the development of foundational models for Artificial Intelligence, native in Spanish and co-official languages.
In January 2024, ArisGlobal, an innovative life sciences technology company and creator of LifeSphere(R), revealed details about its Advanced Intake powered by LifeSphere NavaX, the company's next-generation advanced cognitive computing engine.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.